( May 7, 2025, 11:43 AM EDT) -- WASHINGTON, D.C. — A Delaware federal judge abused discretion by ordering a defendant pharmaceutical company to perform no further experimentation on its medication for people with narcolepsy that a jury found infringed on a competitor’s product, a Federal Circuit U.S. Court of Appeals panel found May 6, holding that the finding is at odds with the “plain language and purposes of the Hatch-Waxman Act.”...